Vaxart, Inc.
General ticker "VXRT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $117.8M (TTM average)
Vaxart, Inc. follows the US Stock Market performance with the rate: 21.5%.
Estimated limits based on current volatility of 2.2%: low 0.50$, high 0.52$
Factors to consider:
- Total employees count: 65 (-38.1%) as of 2025
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Operational and conduct risks, Operating losses, Clinical trial failure, Regulatory and compliance, Capital shortage
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.26$, 0.78$]
- 2026-12-31 to 2027-12-31 estimated range: [0.34$, 0.94$]
Financial Metrics affecting the VXRT estimates:
- Positive: with PPE of -1.2 at the end of fiscal year the price was neutral
- Positive: -4.23 < Operating profit margin, % of 7.62
- Positive: 6.77 < Operating cash flow per share per price, % of 9.46
- Positive: Inventory ratio change, % of -5.20 <= -0.75
- Positive: Investing cash flow per share per price, % of 20.39 > -0.64
- Positive: Return on assets ratio (scaled to [-100,100]) of 8.07 > 6.06
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term VXRT quotes
Long-term VXRT plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $7.38MM | $28.70MM | $237.26MM |
| Operating Expenses | $90.73MM | $94.99MM | $219.18MM |
| Operating Income | $-83.35MM | $-66.29MM | $18.07MM |
| Non-Operating Income | $1.14MM | $-0.40MM | $-1.27MM |
| Interest Expense | $1.45MM | $2.97MM | $2.82MM |
| R&D Expense | $68.14MM | $74.21MM | $201.58MM |
| Income(Loss) | $-82.20MM | $-66.69MM | $16.80MM |
| Taxes | $0.26MM | $0.26MM | $0.48MM |
| Net Income(Loss)* | $-82.47MM | $-66.95MM | $16.33MM |
| Stockholders Equity | $57.80MM | $58.92MM | $87.80MM |
| Assets | $91.83MM | $166.39MM | $186.08MM |
| Operating Cash Flow | $-70.45MM | $-44.76MM | $7.71MM |
| Capital expenditure | $1.87MM | $0.55MM | $0.14MM |
| Investing Cash Flow | $43.95MM | $-21.32MM | $16.63MM |
| Financing Cash Flow | $15.24MM | $56.56MM | $4.24MM |
| Earnings Per Share** | $-0.17 | $-0.14 | $0.07 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.